Glioblastoma is the most prevalent and aggressive type of brain cancer accounting for 15% of all primary brain tumours. A lack of curative treatment options, coupled with its invasive nature and resistance to treatment means about 90% of patients die within 5 years of diagnosis. Identified as a possible treatment option, Casein Kinase 2 inhibitors have shown promise as a potent curative option for the disease. Combining a solution containing the inhibitor with a suitable polymer causes formation of nanoparticles that encapsulate the inhibitor. These nanoparticles can then be injected directly into the brain to target the glioblastoma cells.